Ark Biopharmaceutical Gains Approval for Azstarys® to Treat ADHD in China Ark Biopharmaceutical has achieved a significant milestone with the approval of Azstarys® by China's NMPA for ADHD treatment, marking a vital new option for patients.

Ark Biopharmaceutical Gains Approval for Azstarys® to Treat ADHD in China #China #Shanghai #Azstarys #ADHD_treatment #Ark_Biopharmaceutical

HarmonEyes Acquires iFocus Health: A New Era for ADHD Treatment Powered by AI HarmonEyes has successfully acquired iFocus Health, enhancing ADHD treatment with AI eye-tracking technology for real-time care assessment.

HarmonEyes Acquires iFocus Health: A New Era for ADHD Treatment Powered by AI #USA #Bethesda #ADHD_treatment #HarmonEyes #iFocus_Health

ArkBio's Azstarys Drug Application for ADHD Receives Priority Review from China NMPA Shanghai Ark Biopharmaceutical's Azstarys, a new ADHD treatment combining two active ingredients, has received Priority Review status in China, promising better management for patients.

ArkBio's Azstarys Drug Application for ADHD Receives Priority Review from China NMPA #China #Shanghai #ArkBio #Azstarys #ADHD_treatment